Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 20 articles:
HTML format
Text format



Single Articles


    August 2017
  1. MOYO TK, Wilson CS, Moore DJ, Eischen CM, et al
    Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Oncogene. 2017;36:4653-4661.
    PubMed     Text format     Abstract available


    July 2017
  2. GUO X, Koff JL, Moffitt AB, Cinar M, et al
    Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
    Oncogene. 2017;36:4224-4232.
    PubMed     Text format     Abstract available


  3. WU TS, Tan CT, Chang CC, Lin BR, et al
    B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  4. TONELLI C, Morelli MJ, Sabo A, Verrecchia A, et al
    Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas.
    Oncogene. 2017;36:2921-2929.
    PubMed     Text format     Abstract available


  5. GOTO H, Kariya R, Kudo E, Okuno Y, et al
    Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.
    Oncogene. 2017 May 8. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  6. PUCCETTI MV, Fischer MA, Arrate MP, Boyd KL, et al
    Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution.
    Oncogene. 2017;36:2553-2564.
    PubMed     Text format     Abstract available


  7. DAI L, Lin Z, Qiao J, Chen Y, et al
    Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
    Oncogene. 2017 May 1. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  8. SOCHALSKA M, Schuler F, Weiss JG, Prchal-Murphy M, et al
    MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
    Oncogene. 2017;36:2066-2073.
    PubMed     Text format     Abstract available


    February 2017
  9. SAUER M, Schuldner M, Hoffmann N, Cetintas A, et al
    CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
    Oncogene. 2017;36:933-941.
    PubMed     Text format     Abstract available


    October 2016
  10. MURGA-ZAMALLOA CA, Mendoza-Reinoso V, Sahasrabuddhe AA, Rolland D, et al
    NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  11. LINKE F, Zaunig S, Nietert MM, von Bonin F, et al
    WNT5A: a motility-promoting factor in Hodgkin lymphoma.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  12. LI Y, Bouchlaka MN, Wolff J, Grindle KM, et al
    FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
    Oncogene. 2016 May 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    February 2016
  13. GIBAJA V, Shen F, Harari J, Korn J, et al
    Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
    Oncogene. 2016;35:558-66.
    PubMed     Text format     Abstract available


    January 2016
  14. MURALIDHARAN SV, Bhadury J, Nilsson LM, Green LC, et al
    BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    December 2015
  15. VALENTE LJ, Grabow S, Vandenberg CJ, Strasser A, et al
    Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Oncogene. 2015 Dec 7. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    November 2015
  16. O'HAYRE M, Inoue A, Kufareva I, Wang Z, et al
    Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Galpha/RhoA axis in B cells.
    Oncogene. 2015 Nov 30. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  17. MENG X, Carlson NR, Dong J, Zhang Y, et al
    Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Oncogene. 2015;34:5709-17.
    PubMed     Text format     Abstract available


    October 2015
  18. HANEY SL, Hlady RA, Opavska J, Klinkebiel D, et al
    Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis.
    Oncogene. 2015;34:5436-46.
    PubMed     Text format     Abstract available


    September 2015
  19. WADE MA, Sunter NJ, Fordham SE, Long A, et al
    c-MYC is a radiosensitive locus in human breast cells.
    Oncogene. 2015;34:4985-94.
    PubMed     Text format     Abstract available


  20. SHAIN KH, Dalton WS, Tao J
    The tumor microenvironment shapes hallmarks of mature B-cell malignancies.
    Oncogene. 2015;34:4673-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: